Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
In this study for elderly myeloma patients lenalidomide plus low-dose dexamethasone until
progression is being compared with age-adjusted tandem high-dose melphalan 140 mg/m²
augmented by induction with 3 cycles of lenalidomide plus low-dose dexamethasone before
transplantation and lenalidomide maintenance after transplantation.
Phase:
Phase 3
Details
Lead Sponsor:
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH